View Clinical Trial (Medical Research Study)

A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients - NCT01091506-(Clinical Trial 595695)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Boston
State:  
MA
Zip Code:
Conditions: Schizophrenia
Purpose: This study is a 12-week, double-blind, placebo-controlled trial of L-methylfolate 15 mg/d supplementation in schizophrenia patients with mild or greater negative symptoms. L-methylfolate, a prescription medical food, is the activated form of folate required for conversion of homocysteine to methionine and hence is the optimal form of folate for supplementation, since it eliminates the need for activation by MTHFR. The purpose of this study is to examine the change in plasma L-methylfolate concentrations following a three-month trial of L-methylfolate 15 mg/d compared to placebo.
Study summary: Blood levels of L-methylfolate and biological activity will be evaluated by examining changes in plasma homocysteine concentrations, serum methionine concentrations and changes in brain activation as measured by fMRI.
Criteria: Inclusion Criteria: - Diagnosis of schizophrenia, any subtype - Male of female - Age 18-68 years - Treated with an antipsychotic for at least 6 months at a stable dose for at least 6 weeks - PANSS total score of at least 60, with at least 3 (moderate) on one negative symptom item or on one positive symptom item - Simpson Angus Scale (SAS) for the EPS total score of 12 or less and - A score of 2 (mild) or less on all items of the Calgary Depression Rating Scale (CDRS) - Comprehension of English adequate to complete cognitive testing Exclusion Criteria: - Unable to provide informed consent - CBC results consistent with megaloblastic anemia - Serum creatinine concentration greater than 1.4 - Current use of folate supplementation > 400mcg folate - Alcohol or other substance abuse within 3 months (nicotine allowed) - Current use of any of the following medications: phenobarbital, phenytoin, carbamazepine, valproic acid, fosphenytoin, primidone or pyrimethamine - Positive baseline urine toxic screen, (positive test for PCP, barbiturates, cannabinoids, amphetamines, benzodiazepines, opiates, or cocaine) - Unstable medical illness (exclusionary lab values are listed in Appendix A) - Unstable psychiatric illness - Seizure disorder - Pregnant or nursing, or planning/trying to get pregnant within the next 6 months, and - DSM-IV diagnosis of major depressive disorder
Study is available at: Massachusetts General Hospital (MGH) Schizophrenia Program at Freedom Trail Clinic
Boston, MA
United States

Primary Contact:
Lisa H Raeke, MA
Email: lraeke@partners.org
Phone: 617-912-7840

Secondary Contact:
Lori W Barrentine, MS, PA-C
Email: lbarrentine@pamlab.com
Phone: 985-867-5787
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.